PRS4 Comparative Efficacy of Aclidinium Bromide 400 Mcg Bid Versus Tiotropium 18 Mcg and 5 Mcg QD as Maintenance Bronchodilator Treatment to Relieve Symptoms in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD): A Network Meta-Analysis  by Karabis, A. et al.
COPD phenotypes and history of pneumonia can impact on exacerbation of COPD
in Korea. We need to investigate further prospective studies to reach the concrete
conclusion.
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OBJECTIVES: Omalizumab has been shown to decrease the risk of hospitalisation
or emergency visits in patients with uncontrolled severe allergic asthma as com-
pared to placebo. This longitudinal study observed the conditions under which
omalizumab is prescribed in real-life settings; and assessed whether its use, as an
add-on therapy alongside standard treatments, decreases the risk of severe asth-
matic exacerbations. METHODS: A cohort of adult patients with uncontrolled se-
vere asthma despite optimal treatment with inhaled and oral corticosteroids and a
long-acting beta2-agonist, but no treatment with omalizumab upon entry, was
assembled. Risk of hospitalisation and/or emergency room visits for asthma exac-
erbation was assessed using the Andersen-Gill extension of the Cox model for
repeated events controlling for age, gender, smoking history, body mass index,
gastro-oesophageal reflux, allergic status, allergic rhinitis, treatment, and hospi-
talisation or emergency room visits for asthma in the 2 months prior to omali-
zumab treatment. RESULTS: Overall, 163 physicians recruited 767 patients, of
whom 374 took omalizumab at least once (mean observation period: 20.4 months).
Omalizumab use was associated with an adjusted relative risk of hospitalisation
and/or emergency room visits for asthma of 0.57 (95% confidence interval: 0.43-
0.78). In omalizumab users, the adjusted relative risk of hospitalisation and/or
emergency room visits for asthma during omalizumab treatment versus non-treat-
ment periods was 0.40 (95% confidence interval: 0.28-0.58). CONCLUSIONS:Add-on
omalizumab significantly decreases the risk of hospitalisation/emergency room
visits in patients with uncontrolled severe asthma in the real-life practice.
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OBJECTIVES: To estimate the relative efficacy of a new long-acting muscarinic
antagonist (LAMA), aclidinium bromide 400 g BID (AB400), to tiotropium bromide
18 g (TIO18) and 5 g (TIO5) QD in patients with COPD. METHODS: A systematic
literature search using a predefined strategy in MEDLINE©, EMBASE© and the Co-
chrane Library identified 21 unique placebo-controlled RCTs: TIO18 (16 trials), TIO5
(3 trials) and AB400 (2 trials). Outcomes were change from baseline (CFB) in lung
function (trough FEV1), disease-specific health status by St. George’s Respiratory
Questionnaire (SGRQ) total score, and breathlessness by Transition Dyspnea Index
(TDI) focal score, at 12 and 24 weeks. All trials were analysed simultaneously using
a Bayesian network meta-analysis and relative treatment effects between all reg-
imens were obtained. Meta-regression techniques were included to investigate
dissimilarities in study design and patient characteristics across trials. RESULTS:
In line with the pivotal trials, AB400 was shown to be more efficacious than placebo
on all evaluated endpoints. AB400 showed comparable but numerically greater
improvements at 12 weeks compared to TIO18 in trough FEV1 [difference in CFB
(95% Credible Interval) 0.001L (-0.03,0.03)], SGRQ total score [-0.85 (-3.41,1.75)] and
TDI focal score [0.06 (-0.41,0.52)]. Similar but numerically greater differences were
also seen for AB400 versus TIO18 at 24 weeks in trough FEV1 [0.02L (-0.02,0.08)],
SGRQ total score [-1.84 (-4.21,0.51)] and TDI focal score [0.10 (-0.53,0.73)]. Addition-
ally, AB400 showed similar improvements on these same endpoints versus TIO5
(where data was available). Meta-regression analyses, correcting for differences in
treatment patterns (concurrent ICS, LABA treatment) and COPD severity (baseline
FEV1 percent predicted) across the trials, showed comparable findings as the base
case analysis. CONCLUSIONS: This meta-analysis suggests that maintenance
treatment with aclidinium 400 g BID results in comparable improvements in lung
function, health status, and breathlessness as tiotropium 18 g and 5 g QD in
COPD patients.
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OBJECTIVES: To evaluate the relative efficacy of indacaterol 150g  tiotropium
18g (IND/TIO) versus triple therapies (i.e. tiotropium plus a fixed-dose combina-
tion [FDC] of a long-acting beta2-agonist [LABA] and inhaled corticosteroid [ICS]), a
LABA/ICS FDC alone, and monotherapies, including indacaterol, tiotropium, acli-
dinium, salmeterol, formoterol, and placebo in patients with moderate to severe
chronic obstructive pulmonary disease (COPD) in terms of trough FEV1 at 12 weeks.
METHODS: Several of the treatments to be compared include ICS as part of the
study treatment. Therefore the evidence base was restricted to RCTs not allowing
for concomitant ICS use (for Novartis studies subgroup data for non-ICS users were
included). For this population 23 RCTs were identified based on a systematic liter-
ature review, which were analysed simultaneously using a Bayesian network
meta-analysis. Treatment-by-covariate interactions were included for the propor-
tion of current-smokers to improve similarity of the trials. RESULTS: IND/TIO re-
sulted in a higher change from baseline (CFB) in FEV1 by 0.24L (95%CrI: 0.20, 0.27)
versus placebo at 12 weeks. IND/TIO is likely to be favourable versus salmeterol/
fluticasone 50/500g tiotropium 18g [difference 0.03L (95%CrI: -0.01, 0.07); prob-
ability better: 94%] and comparable to formoterol/budesonide 9/320g  tiotro-
pium 18g [difference 0.02L (95%CrI: -0.02, 0.06); probability better: 80%]. IND/TIO
has a larger CFB than the FDCs alone with an advantage of 0.07L (95%CrI: 0.03, 0.12)
to 0.09L (95%CrI: 0.04, 0.15). IND/TIO also has a higher CFB than the monotherapies
assessed. Out of the 13 regimens evaluated, there is a 77% probability that IND/TIO
is the most efficacious treatment in terms of CFB in FEV1. Results were not sensitive
to adjustment for smokers or to the exclusion of RCTs with concomitant anticho-
linergics or an exacerbation history. CONCLUSIONS: IND/TIO is expected be com-
parable to triple therapies and more efficacious than FDCs and monotherapies in
terms of FEV1 at 12 weeks.
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OBJECTIVES: To compare the prevalence of selected medical conditions in Russia
as estimated using the National Health and Wellness Survey (NHWS) with those
from the medical literature. METHODS: This study used data from the 2011 Russia
NHWS, a cross-sectional survey administered to 10,039 adults living in large Rus-
sian cities recruited through both online and offline methods. All data were self-
reported. Weighted prevalence was estimated through self-report and validated
scales embedded in the questionnaire. Conditions included depression, restless
legs syndrome, and sleep difficulties, among others. Gender differences were also
assessed. NHWS estimates were compared with prevalence estimates taken from
published studies. RESULTS: Twelve-month prevalence estimates of depression
according to self-report were 20% in men and 25% in women, and depression of
moderate or greater severity was identified through Patient Health Questionnaire
(PHQ-9) in 17% of men and 21% of women, both slightly higher than the approxi-
mately 10% and 20% estimates of clinically significant depression in men and
women, respectively, reported by Akarachkova and Vershinina (2010). In NHWS,
restless leg syndrome was reported by 6% and 10% of men and women respectively,
and found to affect 8% of men and 10% of women by Romanova (2008). Difficulty
falling asleep was estimated at 25% of men and 32% of women in NHWS, and 30%
of men and 28% of women (Romanova, 2008). Prevalence for all conditions among
urban Russian adults was much lower across conditions when limited to patients
reporting a diagnosis confirmed by a doctor. CONCLUSIONS: Prevalence estimates
and gender differences calculated from NHWS Russia data were generally similar
to those taken from previous literature, providing initial evidence for its use in
estimating prevalence of disease in urban Russia. Reports of experiencing a condi-
tion were much more common than reports of confirmed diagnosis, suggesting
substantial unmet medical need.
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OBJECTIVES: Examine patient characteristics and patterns of intranasal corticoste-
roid (INS) use among individuals diagnosed with allergic rhinitis (AR) from a large,
US retrospective claims database.METHODS: The i3 Invision™ Data Mart was used
from January 1, 2006 through December 31, 2010. AR patients aged 12 years were
included if they received an aqueous INS formulation (with first such date identi-
fied as index date) and had continuous insurance coverage from 6 months before
through 24 months after index date. Patients diagnosed with chronic rhinitis or
nasal polyps were excluded. Data are descriptive in nature. RESULTS: The sample
consisted of 163,473 individuals with a mean age of 41 years (SD15), 59% female,
and 55% residing in the southern US. Patients were most commonly prescribed
generic fluticasone propionate (44%), mometasone (34%), or triamcinolone (10%)
and had a high degree of related comorbidities, including sinusitis (40%), asthma
(15%), and otitis media (12%). Treatment patterns during the first year after index
date: a mean of 2.1 INS prescriptions were filled (median1.0; SD1.8), adherence
as measured by the medication possession ratio averaged 18% (median8; SD16),
and persistence averaged 135 days (median30; SD134). Furthermore, 7% of pa-
tients switched INS products during their first year of use, with 5% of patients who
initially received generic INS switching to a branded INS product. CONCLUSIONS:
Although INSs are considered the gold standard for symptomatic treatment of AR,
this examination of a large US claims database demonstrated that patients with AR
who filled at least 1 aqueous INS prescription generally did not use their INS for an
extended period of time.
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